HER2 - Negative Breast Cancer - Global Strategic Business Report

The global market for HER2 - Negative Breast Cancer is estimated at US$13.4 Billion in 2023 and is projected to reach US$21.5 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the HER2-negative breast cancer therapeutics market is driven by several factors, including advancements in research and development that have led to new treatment modalities and improved patient outcomes. The increasing prevalence of breast cancer globally, coupled with heightened awareness and early detection efforts, has expanded the patient pool eligible for these therapies. Technological advancements in diagnostic tools and genetic testing enable more precise identification of cancer subtypes and more tailored treatment plans. Additionally, the shift towards personalized medicine and the development of novel drugs targeting specific pathways involved in cancer progression are significant drivers of market growth. Regulatory support and expedited approval processes for breakthrough therapies further facilitate the introduction of innovative treatments. The growing investment in oncology research, coupled with collaborations between pharmaceutical companies and research institutions, continues to fuel the pipeline of potential new therapies. These factors collectively ensure a robust and dynamic market for HER2-negative breast cancer therapeutics, providing hope for better management and improved survival rates for patients worldwide.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Radiation Therapy segment, which is expected to reach US$8.9 Billion by 2030 with a CAGR of a 6.4%. The Hormonal Therapy segment is also set to grow at 7.6% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $3.6 Billion in 2023, and China, forecasted to grow at an impressive 11.1% CAGR to reach $4.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global HER2 - Negative Breast Cancer Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global HER2 - Negative Breast Cancer Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global HER2 - Negative Breast Cancer Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Astrazeneca Pharmaceuticals LP, BeiGene, Beta Pharma, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 61 Featured):

Astrazeneca Pharmaceuticals LP
BeiGene
Beta Pharma
Celcuity
CytomX Therapeutics, Inc.
Daiichi Sankyo Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genentech, Inc.
Incyte Corporation
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Olema Oncology
Pfizer, Inc.
Prelude Therapeutics

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Global Economic Update
HER2 - Negative Breast Cancer - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Breast Cancer Prevalence Provides the Foundation for Growth in the Market
A Review of Advances in Chemotherapy and Hormonal Therapy for HER2-Negative Patients
Global Initiatives to Increase Awareness and Early Screening of Breast Cancer Drive Diagnosis Rates
Development of Targeted Therapies Offering New Hope for Patients
Anti-HER2 Therapies Grow in Popularity and Adoption

4. GLOBAL MARKET PERSPECTIVE

Table 1: World HER2 - Negative Breast Cancer Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for HER2 - Negative Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Radiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Radiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Radiation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 17: USA Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 18: USA Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 19: USA 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

CANADA

Table 20: Canada Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 21: Canada Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 22: Canada 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

JAPAN

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 23: Japan Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 24: Japan Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: Japan 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

CHINA

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 26: China Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 27: China Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 28: China 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

EUROPE

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 29: Europe Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 30: Europe Historic Review for HER2 - Negative Breast Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: Europe 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 32: Europe Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 33: Europe Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: Europe 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

FRANCE

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 35: France Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 36: France Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 37: France 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

GERMANY

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 38: Germany Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: Germany Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 40: Germany 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

ITALY

Table 41: Italy Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 42: Italy Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 43: Italy 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

UNITED KINGDOM

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 44: UK Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: UK Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 46: UK 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

SPAIN

Table 47: Spain Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 48: Spain Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 49: Spain 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

RUSSIA

Table 50: Russia Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: Russia Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 52: Russia 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 53: Rest of Europe Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 54: Rest of Europe Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 55: Rest of Europe 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

ASIA-PACIFIC

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 56: Asia-Pacific Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 57: Asia-Pacific Historic Review for HER2 - Negative Breast Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 58: Asia-Pacific 16-Year Perspective for HER2 - Negative Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
Table 59: Asia-Pacific Recent Past, Current & Future Analysis for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 60: Asia-Pacific Historic Review for HER2 - Negative Breast Cancer by Treatment Type - Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 61: Asia-Pacific 16-Year Perspective for HER2 - Negative Breast Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation, Hormonal Therapy, Chemotherapy and Other Treatment Types for the Years 2014, 2024 & 2030

AUSTRALIA

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

INDIA

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

HER2 - Negative Breast Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Astrazeneca Pharmaceuticals LP
BeiGene
Beta Pharma
Celcuity
CytomX Therapeutics, Inc.
Daiichi Sankyo Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genentech, Inc.
Incyte Corporation
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Olema Oncology
Pfizer, Inc.
Prelude Therapeutics

Table Information

Report Attribute	Details
No. of Pages	205
Published	October 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 13.4 Billion
Forecasted Market Value ( USD ) by 2030	$ 21.5 Billion
Compound Annual Growth Rate	7.0%
Regions Covered	Global

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5348EUR$5,600USD£4,451GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10160EUR$10,640USD£8,457GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16043EUR$16,800USD£13,354GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 61 Featured):

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Global HER-2 Negative Breast Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

HER2 Negative Breast Cancer - Pipeline Insight, 2024

HER2Negative Metastatic Breast Cancer - Pipeline Insight, 2024

Breast Cancer Pipeline Analysis Report

Breast Cancer Drugs Global Market Report 2024